Medicus Pharma Ltd (TSE:MDCX) has released an update.
Medicus Pharma Ltd has initiated a Phase 2 trial, testing its drug SKNJCT-003 in patients with nodular basal cell carcinoma, aiming to enroll 60 subjects across six U.S. sites. The trial follows a successful Phase 1 study where the drug showed promising safety and tolerability, with some participants achieving complete responses.
For further insights into TSE:MDCX stock, check out TipRanks’ Stock Analysis page.
